A Randomised, Descriptive, Open Label, Study Exploring the Relationship Between Gene Expression Signatures With Reactogenicity and Immunogenicity Following Vaccination With Serogroup B Meningococcal Vaccine (4CMenB)
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 03 Apr 2017
At a glance
- Drugs Meningococcal vaccine group B OMV Novartis (Primary)
- Indications Meningococcal group B infections
- Focus Adverse reactions; Pharmacodynamics; Pharmacogenomic
- Acronyms EUCLIDS
- 28 Mar 2017 Planned End Date changed from 1 Dec 2016 to 1 Dec 2017.
- 23 Jun 2016 Planned End Date changed from 1 Jun 2016 to 1 Dec 2016.
- 16 Nov 2015 Planned End Date changed from 1 Dec 2015 to 1 Jun 2016 as reported by ClinicalTrials.gov record.